Y. Yamamura

发表

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

H. Fujiki, Toshiki Miyazaki, Y. Yamamura, 2007, Cardiovascular drug reviews.

OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

T Yamashita, G. Tsujimoto, Y. Yamamura, 1998, The Journal of pharmacology and experimental therapeutics.

Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.

Y. Yamamura, A. Ohnishi, H. Fujihara, 1993, The Journal of clinical investigation.

Effects of Tolvaptan on Systemic and Renal Hemodynamic Function in Dogs with Congestive Heart Failure

H. Fujiki, Y. Yamamura, Shigeki Nakamura, 2011, Cardiovascular Drugs and Therapy.

Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats.

Y. Yamamura, Shigeki Nakamura, Toyoki Mori, 2003, Journal of pharmacological sciences.

Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.

Y. Yamamura, S. Nakamura, H. Ogawa, 1996, Journal of medicinal chemistry.

Gα16 Mimics Vasoconstrictor Action to Induce Smooth Muscle α-Actin in Vascular Smooth Muscle Cells through a Jun-NH2-terminal Kinase-dependent Pathway*

L. Heasley, R. Nemenoff, Y. Yamamura, 1997, The Journal of Biological Chemistry.

Galpha16 mimics vasoconstrictor action to induce smooth muscle alpha-actin in vascular smooth muscle cells through a Jun-NH2-terminal kinase-dependent pathway.

L. Heasley, R. Nemenoff, Y. Yamamura, 1997, The Journal of biological chemistry.

Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.

Y. Yamamura, S. Nakamura, T. Hirano, 2000, The Journal of pharmacology and experimental therapeutics.

Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.

Y. Yamamura, A. Ohnishi, Y. Orita, 1995, The Journal of pharmacology and experimental therapeutics.

Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.

T. Saruta, Y. Yamamura, H. Suzuki, 1994, The American journal of physiology.

Antidiuretic effects of a novel nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to dogs.

Y. Yamamura, Shigeki Nakamura, Toyoki Mori, 2004, Journal of pharmacological sciences.

Characterization of a novel nonpeptide vasopressin V2‐agonist, OPC‐51803, in cells transfected human vasopressin receptor subtypes

G. Tsujimoto, Y. Yamamura, Shigeki Nakamura, 2000, British journal of pharmacology.

Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.

Y. Yamamura, S. Nakamura, T. Hirano, 2000, The Journal of pharmacology and experimental therapeutics.

Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats.

Y. Yamamura, T. Nozawa, H. Inoue, 1998, Circulation.

Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.

T. Saruta, Y. Yamamura, H. Suzuki, 1993, The American journal of physiology.

Therapeutic and diagnostic potential of a vasopressin‐2 antagonist for impaired water handling in cirrhosis

Y. Yamamura, A. Ohnishi, K. Okada, 1998, Clinical pharmacology and therapeutics.

Tolvaptan, an orally active non‐peptide arginine vasopressin V2 receptor antagonist, reduces ascites in rats with chronic liver injury

H. Fujiki, Toshiki Miyazaki, Y. Yamamura, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.

H. Fujiki, Toshiki Miyazaki, Y. Yamamura, 2005, Endocrinology.

7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.

Y. Yamamura, S. Nakamura, T. Onogawa, 1999, Bioorganic & medicinal chemistry.

OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.

Y. Yamamura, Shigeki Nakamura, Toyoki Mori, 1991, Science.

OPC-21268 antagonizes arginine vasopressin-induced vasoconstrictor response in the spinally-anesthetized dog.

Y. Yamamura, S. Nakamura, T. Onogawa, 1995, Japanese journal of pharmacology.

Anti-hypertensive activity and action on endothelium-dependent relaxation of OPC-13340, a new potent 1,4-dihydropyridine Ca antagonist, in rats

Y. Yamamura, Toyoki Mori, Y. Yabuuchi, 1990 .

Pranidipine, a new 1, 4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta

Y. Nakaya, H. Fujiki, Y. Yamamura, 2004, Molecular and Cellular Biochemistry.

Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor.

G. Tsujimoto, Y. Yamamura, Toyoki Mori, 2006, American journal of physiology. Endocrinology and metabolism.

[Tolvaptan, a vasopressin V2 receptor antagonist, is the world's first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)].

H. Fujiki, Y. Yamamura, K. Hattori, 2022, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats.

T. Saruta, Y. Yamamura, H. Suzuki, 1994, Clinical science.

Chronic and selective vasopressin blockade in spontaneously hypertensive rats.

T. Saruta, Y. Yamamura, H. Suzuki, 1994, The American journal of physiology.

Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

Yoshitaka Yamamura, Y. Yamamura, Shigeki Nakamura, 1992, British journal of pharmacology.

OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats.

Y. Yamamura, S. Nakamura, T. Onogawa, 1994, Hypertension.

Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.

A. Itai, Y. Yamamura, S. Nakamura, 2000, Journal of medicinal chemistry.

Characterization of orally active nonpeptide vasopressin V(2) receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin- 5-yl]-N-isopropylacetamide.

Y. Yamamura, Shigeki Nakamura, Toyoki Mori, 2002, Journal of medicinal chemistry.

Antihypertensive Activity of OPC‐13340, a New Potent and Long‐Acting Dihydropyridine Calcium Antagonist, in Rats

Y. Yamamura, Toyoki Mori, Y. Yabuuchi, 1990, Journal of cardiovascular pharmacology.

Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury

H. Fujiki, Y. Yamamura, M. Ishikawa, 2014, The Journal of Pharmacology and Experimental Therapeutics.

The Discovery of Samsca® (Tolvaptan): The First Oral Nonpeptide Vasopressin Receptor Antagonist

Y. Yamamura, K. Kondo, 2012 .

Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.

Y. Yamamura, H. Ogawa, H. Yamashita, 1993, Journal of Medicinal Chemistry.

Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury

H. Fujiki, Y. Yamamura, M. Ishikawa, 2014, The Journal of Pharmacology and Experimental Therapeutics.